Update on the interNational Anaplastic Thyroid cancer Tissue bank project (iNATT)


The interNational Anaplastic Thyroid Cancer Tissue Bank and Database project (iNATT) was launched in the UK in 2013 and extended internationally in 2014. The project offers patients with this diagnosis a rare opportunity to participate in research.  By collecting tissue and blood samples along with clinical information from across the UK and from international centres we will be able to gather a significant amount of data which will help us make progress with research in to this difficult to treat disease. We hope to learn more about why and how this type of cancer develops so that we can... Continue reading

Update on ITOG Selumetinib Trial

Dr. Alan Ho

The selumetinib clinical trial led by Dr. Alan Ho of Memorial Sloan Kettering Cancer Center in New York, NY is now open. The trial evaluates the effectiveness of selumetinib to enhance uptake of radioactive iodine (RAI) for treatment of advanced thyroid cancer. This is a large, multicenter, investigator-initiated, randomized, placebo controlled Phase II trial of selumetinib in patients with RAI-avid, recurrent or metastatic thyroid cancer of follicular cell origin. Radioiodine is a key therapy for patients with metastatic thyroid cancer of follicular origin, yet many patients have tumors... Continue reading

Initial Findings of ITOG's First Clinical Trial

Dr. Manisha H. Shah

Preliminary results of the first clinical trial initiated by ITOG have been evaluated, marking a major accomplishment for ITOG. The goal of this multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, is to examine whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with cabozantinib. Dr. Shah reported the initial findings this October at the 15th International Thyroid Congress in Lake Buena Vista, Florida. The abstract of her talk was titled: Cabozantinib in Patients with Radioiodine-Refractory... Continue reading

Philanthropy Exceeds $2.5 Million

Support for the ITOG mission continues to grow with generous contributions from even more supportive donors. Most donations have come from patients, and families of patients, with thyroid cancer who believe that the multi-disciplinary team of ITOG physicians are making a significant difference in improving the treatment of the most challenging thyroid cancers. ITOG received its single largest donation of $500,000 in 2014 from an anonymous donor. Many of ITOG’s member physicians and scientists have also donated to support the organization. Future plans for use of these philanthropic funds not... Continue reading

ITOG Scientists Outline Important Research Benchmarks

ITOG is dedicated to improving the survival and quality of life among patients with thyroid cancer. As part of that mission, the Correlative Sciences Committee of the ITOG has thoughtfully developed a position statement regarding the need for robust correlative studies in thyroid cancer clinical trials to further improve the care of patients with this disease. Correlative science is used to reveal relationships between molecular biomarkers, such as changes in genes and proteins, and clinical outcomes. While meaningful advances have been made in treating metastatic and progressive thyroid... Continue reading

Leadership within ITOG Expands

Recognizing Dr. Sherman's leadership

The Board of Directors has elected Dr. Lori Wirth as the new chair of ITOG. She will serve a three-year term. Dr. Wirth previously chaired the Protocol Committee, the group responsible for selecting ITOG clinical trials, and also served as ITOG Secretary. Dr. Wirth is the Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital. Dr. Manisha Shah, an oncologist at Ohio State University, joins the Executive Committee as the newly elected ITOG Secretary. Dr. Shah was previously chair of the Membership Committee and served on the Protocol Committee, all while... Continue reading

A Truly International Annual Meeting

For the first time in ITOG history, the Annual Meeting was held in Europe. ITOG members Dr. Sebastiano Filetti and Dr. Martin Schlumberger hosted an exceptional two-day gathering at Sapienza Università di Roma in Rome, Italy, where Dr. Filetti is a member of the faculty. The inspiring agenda was complete with presentations of groundbreaking research, the latest results from clinical trials, and innovative approaches employed in other cancer diagnoses that could be translated for thyroid cancer research. Dr. Thomas Giordano gave an extremely informative talk on the molecular characterization... Continue reading

Cabozantinib impact on thyroid tumor shrinkage

Dr. Manisha Shah, ITOG investigator, discusses the impact of cabozantinib on thyroid tumor shrinkage.  Watch the video here: Click here for the video.  

Clinical trial of a very well tolerated drug for an uncommon form of thyroid cancer

The drug Pioglitazone (Actos) is being used in a clinical trial for thyroid cancers that contain a specific mutation called PAX8-PPARgamma. PAX8-PPARgamma is uncommon, but is found in some thyroid cancers of the following types: follicular; follicular variant of papillary; and poorly differentiated. An exciting aspect of this trial is that pioglitazone has few if any side effects, and in fact it is FDA-approved for the long term therapy of diabetes. The only potentially significant side effects are mild fluid retention and mild weight gain. The drug is specific for PAX8-PPARgamma and is not... Continue reading

Molecular characterization of thyroid cancers reported at ITOG Annual Meeting

Thomas Giordano

The 2015 ITOG International Meeting was recently held in Rome, Italy, where Dr. Thomas Giordano presented the lead talk on a new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas (TCGA) Research Network, a federally funded project to elucidate the molecular characterization of various cancer types. Dr. Giordano’s findings are extremely important to the thyroid cancer community and will potentially change the way thyroid cancers are classified and diagnosed. Further, the identification of new markers of aggressive tumors could allow for better targeting of tailored... Continue reading

FDA Approves Lenvima for Thyroid Cancer based on SELECT results

A large, multi-center phase 3 study (SELECT trial) has found that patients with progressive, iodine refractory differentiated thyroid cancer have markedly improved progression free survival (PFS) when treated with lenvatinib, an oral tyrosine kinase inhibitor. Multiple ITOG members participated in the study, including lead author, Dr. Martin Schlumberger and senior author, Dr. Steven I. Sherman, current Chairman of ITOG.  The study, funded by the Eisai, the manufacturer of lenvatinib, was published in the New England Journal of Medicine, on February 12, 2015. On February 13th the FDA... Continue reading

ITOG Trial #1 Completes Enrollment

The first clinical trial initiated by ITOG in the fall of 2013 has completed its planned enrollment, marking a major accomplishment for ITOG.  The goal of this multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, is to examine whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with cabozantinib. 

 This investigator-initiated clinical trial is truly a collaborative endeavor and every site has participated actively in the process. These efforts have facilitated an impressive timeline in which it took... Continue reading

Fall 2014 Newsletter

The 2014 Fall newsletter is here with important updates on our Selumetinib clinical trial, the Ruane Family's invovlement in ITOG, an update on the Annual Meeting, affiliation with the European Organization for Research and Treatment of Cancer (EORTC), updates on the Cabozantinib clinical trial, and a remembrance of Rick Abrams.  See the full newsletter in PDF by following this link:

ITOG Investigators Identify Novel Mutations in Thyroid Cancers That Could Lead to New Therapies

Recent publications from the laboratories of three separate ITOG members have reported the presence of a new type of mutation in certain thyroid cancers that could lead to use of specific use of certain drugs targeting that genetic abnormality.  Mutations in the gene ALK have previously been identified in certain lymphomas and types of lung cancer, and patients whose tumors harbor those mutations have often responded well to therapy with ALK inhibitors such as crizotinib.  Generally, these mutations are rearrangements of DNA, bringing parts of two genes together to create an active new gene... Continue reading

Update on ITOG’s First Clinical Trial

ITOG's first clinical trial has reached 50% of patient accrual. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University,examines whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with Cabozantinib. ITOG opened its first clinical trial one year ago for treatment of differentiated thyroid cancer.  NCI9312/OSU12154/RU241210I is an investigator-initiated, multicenter, open label, phase II trial of Cabozantinib in patients with radioiodine-refractory, differentiated thyroid cancer (DTC), who progressed on... Continue reading



International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495